Hypersensitivity to any of the components of Tareg.
Use in Pregnancy & Lactation: Due to the mechanism of action of angiotensin II antagonists, a risk for the fetus cannot be excluded. In utero exposure to angiotensin-converting enzyme (ACE) inhibitors given to pregnant women during the 2nd and 3rd trimesters has been reported to cause injury and death to the developing fetus. As for any drug that also acts directly on the renin-angiotensin-aldosterone system (RAAS), Tareg should not be used during pregnancy. If pregnancy is detected during therapy, Tareg should be discontinued as soon as possible.
It is not known whether valsartan is excreted in human milk. Valsartan was excreted in the milk of lactating rats. Thus, it is not advisable to use Tareg in lactating mothers.